recommended a patient-specific treatment plan that was not part of NCCN. Specific substitutions such as Capecitabine for 5-FU, Carboplatin for Cisplatin, and Paclitaxel for Docetaxel that were not part of NCCN were made to for patient tolerance of therapy
Search Results
Naresh Ramarajan, CS Pramesh, Gitika Srivastava, Vikas Ostwal, Anant Ramaswamy, Aju Mathew, Mahesh Goel, Supriya Chopra, BJ Sunil, Durgatosh Pandey, Rajendra A. Badwe, and Bhawna Sirohi
Benjamin E. Greer, Wui-Jin Koh, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, John Chan, Kathleen R. Cho, Larry Copeland, Marta Ann Crispens, Nefertiti DuPont, Patricia J. Eifel, David K. Gaffney, Warner K. Huh, Daniel S. Kapp, John R. Lurain III, Lainie Martin, Mark A. Morgan, Robert J. Morgan Jr., David Mutch, Steven W. Remmenga, R. Kevin Reynolds, William Small Jr., Nelson Teng, and Fidel A. Valea
to single-agent platinum therapy. 111 , 112 Cisplatin-based combination chemotherapy regimens, such as cisplatin/paclitaxel and cisplatin/topotecan, have been extensively investigated in clinical studies. 111 , 112 , 114 – 116 A randomized phase
Ajeet Gajra, Alissa S. Marr, and Apar Kishor Ganti
study evaluating carboplatin and 1 of 2 paclitaxel formulations in treatment-naïve patients with advanced non-small cell lung cancer (NSCLC) and a marginal PS found a significant difference in OS based on the geographic location of the patients. 8
Robert W. Carlson and on behalf of the NCCN Breast Cancer Panel
cancer. These include nab -paclitaxel, eribulin, and ixabepilone. Evolution of HER2-Targeted Therapy The use of trastuzumab, a humanized monoclonal antibody targeting the extracellular domain of HER2, in combination with chemotherapy in the
David M. Dunning and Thomas A. Paivanas
://www.ama-assn.org/ama/pub/category/3113.html . Accessed November 2005 . 10. Langer CJ Leighton JC Comis RL . Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response, and survival analysis . J Clin
Rosalyn A. Juergens and Julie R. Brahmer
CP . Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer . N Engl J Med 2002 ; 346 : 92 – 98 . 4. Sandler AB Gray R Brahmer J . Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or
pharmacokinetics of carboplatin and pralatrexate used in combination Contact: Marcela G. del Carmen, MD, MPH • 617-724-4800 • mdelcarmen@partners.org ClinicalTrials.gov Identifier: NCT01188876 Neoadjuvant Weekly nab-Paclitaxel (Abraxane) Plus
scientific peer-review process and are overseen by the ORP. NCCN studies funded through the grant mechanism are highlighted below. Neoadjuvant Weekly nab-Paclitaxel (Abraxane) Plus Carboplatin Followed by Doxorubicin Plus Cyclophosphamide With
Vinod Ravi, Eric M. Sanford, Wei-Lien Wang, Jeffrey S. Ross, Naveen Ramesh, Andrew Futreal, Shreyaskumar Patel, Phillip J. Stephens, Vincent A. Miller, and Siraj M. Ali
disease. The patient was initially treated with paclitaxel at 80 mg/m 2 weekly; however, he was unable to tolerate paclitaxel weekly without a treatment break. He was therefore maintained on paclitaxel at the 80 mg/m 2 dose, cycling 2 weeks on and 1 week
Thomas Olencki
the combination of high-dose celecoxib and paclitaxel, cetuximab, and erlotinib. However, he noted that further research is needed to confirm early encouraging findings for these agents. The benefits of high-dose celecoxib ( Figure 1 ) and paclitaxel
